Feature | December 26, 2012

Congress Passes American Medical Isotope Production Act

SNMMI commends Sens. Jeff Bingaman and Lisa Murkowski for leadership

December 26 , 2012 — Congress last week affirmed its dedication to securing a sustainable, domestic supply of molybdenum-99 (Mo-99) as it passed the American Medical Isotope Production Act of 2011 (S.99). The bill, sponsored Sen. Jeff Bingaman (D-N.M.), chair of the Senate Committee on Energy and Natural Resources, and Sen. Lisa Murkowski (R-Ark), was passed out of the Senate by Unanimous Consent and referred to the House Subcommittee on Energy and Environment. S.99 was included in the Conference Agreement for the National Defense Authorization Act for fiscal year 2013. The president is expected to sign the final legislation.

The bill will establish a technology-neutral program to support the production of Mo-99 for medical uses in the United States by non-federal entities. It also calls for the United States to phase out the export of highly enriched uranium for the production of medical isotopes over a period of seven years.

“Sens. Bingaman and Murkowski have shown unwavering commitment to ensuring a stable isotope supply for the United States,” said Frederic H. Fahey, DSc, president of the Society of Nuclear Medicine and Molecular Imaging (SNMMI). “In order for our patients to receive the best medical care, it’s essential that a reliable supply of Mo-99 be available in the United States. We greatly appreciate their efforts in seeing this bill come to fruition.” Also instrumental in moving the legislation forward were Energy and Commerce Chair Fred Upton (MI-6) and Congressman Ed Markey (MA-7).

Mo-99 is an isotope that decays to technetium-99m (Tc-99m), which is used in more than 16.7 million procedures in the United States each year. Tc-99m is utilized in the detection of heart disease, detection and staging of cancer, detection of thyroid disease, study of brain and kidney function, and imaging of stress fractures.

There are currently only eight foreign producers of Mo-99 approved by the U.S. Food and Drug Administration to import the product into the United States — and there are no domestic facilities exist dedicated to the production of Mo-99 for medical uses. The aging foreign reactors regularly experience significant ongoing maintenance issues — frequently causing these reactors to go off-line. In 2009-2010, the Unites States experienced a shortage of Mo-99 that led to the disruption or delay of nuclear medicine procedures for an estimated 50,000 patients each day.

For more information: www.snmmi.org

Related Content

ASRT Supports Radiopharmaceutical Reimbursement Bill
News | Radiopharmaceuticals and Tracers | August 02, 2019
The American Society of Radiologic Technologists (ASRT) announced its support for House Resolution (HR) 3772, a measure...
NorthStar Medical Radioisotopes Completes Construction on Beloit, Wis. Molybdenum-99 Processing Facility
News | Radiopharmaceuticals and Tracers | July 16, 2019
NorthStar Medical Radioisotopes LLC  announced completion of construction on its 20,000-square-foot molybdenum-99 (Mo-...
BGN Technologies Introduces Novel Medical Imaging Radioisotope Production Method
News | Radiopharmaceuticals and Tracers | June 05, 2019
BGN Technologies, the technology transfer company of Ben-Gurion University (BGU), introduced a novel method for...
New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent
News | Radiopharmaceuticals and Tracers | May 17, 2019
Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in...
Shine Medical Technologies Breaks Ground on U.S. Medical Isotope Production Facility
News | Radiopharmaceuticals and Tracers | May 10, 2019 | Jeff Zagoudis, Associate Editor
Shine Medical Technologies Inc. broke ground on their first medical isotope production facility in Janesville, Wis. U.S...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
The Council on Radionuclides and Radiopharmaceuticals Inc. (CORAR) — the voice of the radionuclide, radiopharmaceutical...
Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 26, 2018 | Dave Fornell
February 8, 2018 — The U.S.
ARTMS Products Inc. and GE Healthcare Team Up to Expand Cyclotron-Produced Radioisotopes
News | Radiopharmaceuticals and Tracers | August 30, 2017
ARTMS Products Inc. signed a strategic partnership with GE Healthcare around ARTMS’ proprietary QUANTM99 Irradiation...
Lantheus and GE Healthcare Sign Agreement for Worldwide Development, Commercialization of Flurpiridaz F-18
News | Radiopharmaceuticals and Tracers | May 22, 2017
Lantheus Holdings Inc., parent company of Lantheus Medical Imaging Inc., and GE Healthcare announced the signing of a...
Australian Team Finds New Method for Producing PET Radiotracers in Higher Radiochemical Yields
News | Radiopharmaceuticals and Tracers | April 28, 2017
Researchers at the Australian Nuclear Science and Technology Organisation (ANSTO) have led the development of a new...
Overlay Init